Τίτλος:
Shedding light on developmental drugs for idiopathic pulmonary fibrosis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Introduction: Idiopathic pulmonary fibrosis (IPF) is an age-related disease of unknown cause. The disease is characterized by relentless scarring of the lung parenchyma resulting in respiratory failure and death. Two antifibrotic drugs (pirfenidone and nintedanib) are approved for the treatment of IPF worldwide, but they do not offer a cure and are associated with tolerability issues. Owing to its high unmet medical need, IPF is an area of dynamic research activity. Areas covered: There is a growing portfolio of novel therapies that target different pathways involved in the complex pathogenesis of IPF. In this review, we discuss the mechanisms of action and available data for compounds in the most advanced stages of clinical development. We searched PubMed for articles on this topic published from 1 January 2000, to 6 June 2020. Expert opinion: The approval of pirfenidone and nintedanib has fueled IPF drug discovery and development. New drugs are likely to reach the clinic in the near future. However, numerous challenges remain; the lack of animal models that reproduce the complexity of human disease and the poor translation of preclinical and early-phase positive effects to late stage clinical trials must be tackled. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Spagnolo, P.
Bonella, F.
Ryerson, C.J.
Tzouvelekis, A.
Maher, T.M.
Περιοδικό:
Expert Opinion on Investigational Drugs
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
alphaVbeta6 integrin inhibitor; antifibrotic agent; belumosudil; bms 986263; cc 90001; fezagepras; glpg 1205; ianalumab; immunomodulating agent; iw 001; nintedanib; pamrevlumab; pirfenidone; rg6354; td 139; unclassified drug; vay 736; ziritaxestat; indole derivative; nintedanib; nonsteroid antiinflammatory agent; pirfenidone; protein kinase inhibitor; pyridone derivative, drug approval; drug development; drug efficacy; drug tolerability; fibroblast; fibrosing alveolitis; human; immunotherapy; lung alveolus macrophage; male; nonhuman; pathogenesis; patient; patient monitoring; Review; systematic review; animal; drug development; fibrosing alveolitis; pathophysiology, Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Development; Drug Discovery; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones
DOI:
10.1080/13543784.2020.1782885
